Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endothelin receptor antagonists: current status and perspectives.

M Clozel1

  • 1Actelion Ltd., Innovation Center; Allschwil, Switzerland.

Journal of Cardiovascular Pharmacology
|September 8, 2000
PubMed
Summary

Endothelin (ET) receptor antagonists show promise for treating heart failure, hypertension, and cerebral vasospasm. Early clinical results are encouraging, supporting further development of these oral medications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurements of blood pressure and electrocardiogram in conscious freely moving guineapigs: a model for screening QT interval prolongation effects.

Laboratory animals·2007
Same author

The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat.

Xenobiotica; the fate of foreign compounds in biological systems·2007
Same author

Heart failure--an epidemic of the 21st century? 25th Institut Pasteur Euroconference. 26-27 June 2000, Paris, France.

IDrugs : the investigational drugs journal·2005
Same author

The pharmacology of bosentan.

Expert opinion on investigational drugs·2005
Same author

Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure.

Acta pharmacologica Sinica·2001
Same author

Endothelin mediates the altered renal hemodynamics associated with experimental congestive heart failure.

Journal of cardiovascular pharmacology·2001

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Neurology

Background:

  • Endothelin (ET) is implicated in various diseases.
  • ET receptor antagonists are potential therapeutic agents.
  • Clinical validation is needed for ET receptor antagonists.

Purpose of the Study:

  • To evaluate preclinical and clinical results of an orally active ET receptor antagonist.
  • To assess efficacy in congestive heart failure, systemic hypertension, and cerebral vasospasm.

Main Methods:

  • Preclinical studies.
  • Clinical trials in three therapeutic fields.

Main Results:

  • The first orally active ET receptor antagonist was developed.

Related Experiment Videos

  • Encouraging clinical results were observed in congestive heart failure, systemic hypertension, and cerebral vasospasm.

    • Conclusions:

    • ET receptor antagonists show potential for treating congestive heart failure, systemic hypertension, and cerebral vasospasm.
    • Further clinical development is warranted based on positive outcomes.